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Abstract
Introduction At the time when metastatic disease is identified,
assessment of human epidermal growth factor receptor (HER)2
status might help to optimize treatment decisions if HER2 status
was not determined at first diagnosis and if HER2 positivity has
been acquired during disease progression. Within this context,
determination of serum HER2 or evaluation of HER2 status in
circulating tumor cells (CTCs) may be of clinical relevance
because metastatic tissue may be difficult to obtain for analysis
as a result of its localization. The aim of this study was therefore
to determine the HER2 status in serum and corresponding
CTCs in patients with metastatic breast cancer whose primary
tumors were HER2 negative or of unknown HER2 status.
Methods Blood samples were obtained from 77 metastatic
breast cancer patients with negative (n = 44) or unknown (n =
33) HER2 status. Serum HER2 was determined using a
commercial HER2/neu ELISA kit. CTCs were detected by slide-
based assay using immunomagnetic enrichment and
characterized by phenotyping and genotyping. Alternatively, a
commercial kit, based on RT-PCR, was used to detect and
characterize CTCs.
Results Twenty out of 77 patients with metastatic disease had
elevated serum levels of HER2. Blood samples could be
analyzed for the presence of CTCs in 67 patients. Eight out of
21 patients with detectable CTCs exhibited HER2 amplification.
Twenty-three out of 77 patients were HER2 positive using at
least one method. Concordance between HER2 status of CTCs
and serum HER2 was observed in 15 of 21 patients (71%). In
six patients conflicting results were obtained. Three patients
with elevated serum HER2 status had HER2-negative CTCs,
whereas three patients with HER2-positive CTCs had normal
serum HER2 levels.
Conclusion A subgroup of patients with initially negative or
unknown HER2 status can have elevated serum HER2 levels
and/or HER2-positive CTCs at the time of development of
metastatic disease. Although only a small number of patients
were studied, our observations are of clinical relevance
because, currently, these patients do not have access to HER2-
targeted therapy.
Introduction
Human epidermal growth factor receptor (HER)2 is a trans-
membrane tyrosine kinase growth receptor protein that is
encoded by a proto-oncogene located on chromosome
17q21. The HER2 proto-oncogene is amplified or over-
expressed in approximately 20% to 25% of invasive primary
breast cancers [1-3]. Positive HER2 status has been linked
with aggressive tumor behaviour and resistance to cytotoxic
and endocrine therapies [3-5]. Patients with HER2 amplifica-
tion or over-expression are eligible for treatment with
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trastuzumab (Herceptin®), a monoclonal antibody directed
against HER2. Trastuzumab inhibits neoplastic cell prolifera-
tion in vivo and in vitro and enhances chemosensitivity [6,7]. It
has been approved for clinical use in metastatic breast cancer.
Based on recently reported results from four large trastuzu-
mab trials (Herceptin Adjuvant trial, the North Central Cancer
Treatment Group trial N9831, National Surgical Adjuvant
Project-31, and Breast Cancer International Research Group
006), trastuzumab is also indicated in adjuvant therapy in
HER2-positive primary breast cancer [8-10]. In addition to
trastuzumab, other therapeutic strategies have recently been
developed to target the HER2 protein, such as the tyrosine
kinase inhibitor lapatinib, which appears to have clinical activ-
ity after failure of trastuzumab therapy [11].
The methods used to select patients for HER2-targeted ther-
apy are based on immunohistochemical detection of HER2
over-expression and demonstration of HER2 gene amplifica-
tion by fluorescence in situ hybridization (FISH) in primary tis-
sue [12]. However, the antigenic profile of primary tumors may
be different from that in metastatic disease. A discrepancy
between the primary tumor and distant metastases was
observed in 7% to 20% of cases [13-17]. Therefore, the reas-
sessment of HER2 status at the time of disease progression
might help to optimize treatment by identifying additional
patients who could profit from trastuzumab or other therapeu-
tic approaches targeted against HER2. Biopsy of the meta-
static lesion may not be an option because of its location.
An alternative to invasive tissue analysis is to determine the
serum HER2 status. The extracellular domain of the HER2
receptor is released after cleavage by ADAM (a disintegrin and
metalloproteinase) metalloproteinases and can be determined
in serum using ELISA [18]. Elevated serum HER2 levels are
highly correlated with HER2 over-expression and amplification
in tumor tissue [19]. Another possibility is the evaluation of
HER2 status by immunohistochemistry or FISH of circulating
tumor cells (CTCs), which are frequently detected in the blood
of metastatic breast cancer patients (cell-based assay) [20].
These methods could also be helpful for patients with recur-
rent breast cancer of unknown HER2 status.
Determination of the HER2 status at primary diagnosis was
not a standard procedure until the introduction of trastuzumab
into routine clinical management of breast cancer patients in
the 1990s in many centers, or even until data indicating an
effect of adjuvant trastuzumab treatment emerged in 2005.
Therefore, there remains a significant group of newly diag-
nosed metastatic patients with unknown HER2 status.
Because storage of archival material is limited (for example, 10
years in Germany), primary tumor tissue will not be available
for HER2 assessment in many cases. Therefore, the aim of the
study was to identify metastatic patients with initially negative
or unknown HER2 status who might benefit from HER2-tar-
geted therapy because of HER2 positivity at the time of meta-
static disease. Our approach was to determine the HER2
status in serum and in corresponding CTCs
Materials and methods
Patients
Seventy-seven breast cancer patients who were diagnosed
with metastatic disease either at the Department of Gynecol-
ogy/Obstetrics, Tuebingen (Germany) or at the Department of
Cancer Immunobiology, University of Texas Southwestern
Medical School (Dallas, TX, USA) were included in the analy-
sis. All patients gave informed consent. The blood samples
were obtained before initiation of or change in therapy. The
study protocol was approved by the local ethics committee
(A455/2004).
Inclusion criteria were as follows: breast cancer patients with
first diagnosis of metastatic disease or disease progression;
and either unknown (n = 33) or negative HER2 status (n = 44)
of the primary tumor. In patients with unknown HER2 status (n
= 33), primary archival tumor tissue was requested by the cor-
responding Department of Pathology for HER2 assessment.
Evaluation of serum HER2
Blood was drawn into serum tubes and centrifuged at 1,000
g for 10 minutes at room temperature. Serum samples were
stored at -70°C. Serum HER-2 levels were measured using
the Oncogene Science HER-2 Microtiter ELISA (Oncogene
Science, Cambridge, MA, USA), in accordance with the man-
ufacturer's instructions. A cut-off of 15 ng/ml was chosen
based on the findings of a previous study using the same
assay [21]. The intra-assay coefficent of variation was less
than 5% and the interassay coefficent of variation was 10%.
All serum samples were analyzed in the laboratory of the
Department of Gynecology/Obstetrics, Tuebingen, Germany.
Evaluation of HER2 status of circulating tumor cells
Blood samples from the Department of Cancer Immunobiol-
ogy (Dallas, TX, USA) were analyzed using the ferrofluid assay
(method A). The CTC analysis in patients of the Department of
Gynecology/Obstetrics (Tuebingen, Germany) was con-
ducted using the AdnaTest BreastCancer test (AdnaGen AG,
Langenhagen, Germany; method B). In 10 patients CTC anal-
ysis was not performed because the patients only agreed to
serum HER2 analysis or the blood samples were not provided
by the physicians in accordance with the standard operating
procedures for tumor cell analysis (with respect, for example,
to storage temperature and use of appropriate blood tubes).
Slide-based assay
CTCs were isolated and enriched using a slide-based assay
using ferrofluid linked to antibody to EpCAM (epithelial adhe-
sion molecule) and identified by phenotyping using antibodies
against a pan-cytokeratin (C11; Sigma, Natick, MA, USA) and
HER2 (Her 81; provided by Dr J Uhr, University of Texas
Southwestern Medical School, Dallas, TX, USA). CTCs withAvailable online http://breast-cancer-research.com/content/9/5/R74
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HER2 over-expression were hybridized using a centromeric
probe for chromosome 17 and a locus-specific probe for
HER2 (Vysis, Downers Grove, IL, USA). Details of the CTC-
based assay and the subsequent phenotyping and genotyping
are described in detail elsewhere [20].
RT-PCR based assay
Alternatively, a commercial kit (AdnaTest BreastCancerSe-
lect/Detect; AdnaGen AG) based on RT-PCR was used for
CTC detection and assessment of HER2 status, in accord-
ance with the manufacturer's instructions [22]. AdnaTest
Breast cancerSelect/Detect detects CTCs with a specificity in
excess of 90% and sensitivity greater than 50% above a cut-
off of 0.15 ng/μl for any of the amplicons (epithelial adhesion
molecule: GA733-2, tumor associated mucin: MUC-1, and
HER2RT-PCR and FISH should yield comparable results
because HER2 mRNA over-expression corresponds to gene
amplification and HER2 over-expression, as has been demon-
strated by Walch and coworkers [23].
HER2 status of the metastatic tissue
Re-evaluation of HER2 status of metastatic tissue was not part
of the study and was only performed when requested by the
clinician. Immunohistochemical staining was performed on 3
to 5 μm thick sections of metastatic tissue using a commercial
available ABC kit (Vectastain; Vector Laboratories, Burlin-
game, CA, USA). Primary antibodies (HER2, clone A0485;
Dako, Glostrup, Denmark) were diluted in Tris-HCl (pH 7.5)
and applied in accordance with the manufacturer's instruc-
tions. The degree of staining was scored by a certified pathol-
ogist in accordance with the method recommended for the
DakoHercepTest™. If the Hercep score was 2+, then a FISH
analysis was performed to determine HER2 gene
amplification.
Statistical analysis
The relationship between categorical variables and clinico-
pathologic factors was analyzed using the χ2 test. Statistical
analysis was performed by SPSS (version 11.5; SPSS Inc.,
Chicago, IL, USA). P values less than 0.05 were considered
statistically significant.
Results
Clinical data of the metastatic breast cancer patients
Seventy-seven metastatic breast cancer patients were
included in the analysis. Twenty-five patients had visceral
metastases and 13 patients had bone metastases, whereas
multiple (visceral and bone) metastases were present in 39
patients. The clinical data are summarized in Table 1. Forty-
four patients had a HER2-negative primary tumor. In 33
patients the HER2 status of the primary tumor had not been
determined initially. In patients with unknown HER2 status (n
= 33), primary archival tumor tissue was requested from the
corresponding Department of Pathology for HER2 assess-
ment. Because the interval from first diagnosis exceeded 10
years in most of the breast cancer patients with unknown
HER2 status, tissue was available for HER2 analysis from only
10 of these patients. In four cases archival tissue from a local
recurrence was analyzed for HER2 status. In five of the 14
(36%) patients for whom HER2 status was missing, the pri-
mary tumor was found to be HER2 positive.
Table 1
Clinical data of patients
Number %
Age
<50 years 17 22
≥50 years 60 78
Primary tumor size
pT1 25 32
pT2-4 40 52
PTx 12 16
Nodal status
No 22 29
N1 39 51
Nx 16 21
Grading
I to II 35 45
III 24 31
Unknown 18 23
Estrogen receptor status
Negative 20 26
Positive 45 58
Unknown 12 16
Progesterone receptor status
Negative 25 33
Positive 39 50
Unknown 13 17
HER2 statusa
Negative 44 57
Unknown 33 43
Localization of metastases
Visceral 25 33
Bone 13 17
Multiple/other 39 51
A total of 77 patients were included in this study. aHuman epidermal 
growth factor receptor (HER)2 status at the time of study inclusion; 
in 14 patients HER2 status could be determined from archival tissue 
(five HER2-positive patients and nine HER2-negative patients).Breast Cancer Research    Vol 9 No 5    Fehm et al.
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Serum HER2 levels
Twenty out of the 77 (26%) patients with metastatic disease
had serum HER2 levels above 15 ng/ml. Twelve of these
patients (45%) were initially HER2 negative. HER2 status was
unknown in four of the 20 patients (20%). Elevated HER2 lev-
els were not correlated with initial tumor size, estrogen recep-
tor or progesterone receptor status, and localization of
metastases (data not shown). The percentage of HER2-posi-
tive patients was the same in the group with unknown HER2
status as compared with the group with negative HER2 status
(21% versus 23%). Only one of the five patients with HER2
positive tumors at the time of first diagnosis had a serum
HER2 level below the cut-off. Data are summarized in Table 2.
HER2 status of circulating tumor cells
Blood samples from 67 patients could be analyzed for pres-
ence of CTC. Fifty-one blood samples were analyzed using the
RT-PCR based assay. In 16 cases immunomagnetic separa-
tion followed by cytocentrifugation was performed (slide-
based assay). CTCs were identified in 21 out of 67 (31%)
patients. The CTC detection rate did not correlate with the
detection method (cell-based assay versus RT-PCR based
assay). HER2 status of CTCs was assessed using either RT-
PCR (n  = 51) or double immunofluorescence followed by
FISH (n = 16). HER2 amplification was present in eight out of
21 cases with CTCs (38%). Two of these patients were ini-
tially HER2 negative. In six of these patients the HER2 status
of the primary tumor was unknown.
Correlation between serum HER2 and HER2 status of 
circulating tumor cells
Twenty-three out of 77 (30%) patients had positive HER2 sta-
tus based on either the HER2 status of CTCs or serum. Con-
cordance between HER2 status of CTCs and serum HER2
was observed in 15 out of 21 patients (71%). In six patients
conflicting results were obtained. Three patients with elevated
serum HER2 status had HER2-negative CTCs, whereas three
patients with HER2-amplified CTCs had normal serum HER2
levels (Table 3).
Determination of HER2 status by serum and metastatic 
tissue
Table 4 summarizes the results. HER2 status could be reas-
sessed with metastatic tissue in 10 patients. Two patients
switched from HER2-negative primary tumors to HER2-posi-
tive metastatic sites based on tissue-based immunologic anal-
ysis. Only one of these two patients had elevated serum levels
and HER2-positive CTCs. In contrast, one patient with positive
HER2 status by serum and cell-based assay was HER2 nega-
tive by tissue-based analysis.
Table 2
HER2 re-evaluation by serum HER2, CTC, and metastatic tissue
Primary tissue
HER2 evaluation Total HER2 negative HER2 unknown HER2 positive
Serum HER2 (n =  7 7 ) 7 75 31 95
HER2 negative 57 41 (77) 15 (79) 1 (20)
HER2 positive 20 12 (23) 4 (21) 4 (80)
CTC HER2 (n = 21)a 21 12 6 3
HER2 negative 13 8 (67) 3 (50) 2 (67)
HER2 positive 8 4 (33) 3 (50) 1 (33)
Metastatic tissue (n = 10)b 10 8 2 -
HER2 negative 8 6 (75) 2 (100) -
HER2 positive 2 2 (25) 0 -
1Fifty-six patients were circulating tumor cell (CTC) negative; in 10 patients no CTC evaluation could be performed. bMetastatic tissue was only 
available in 10 patients. HER, human epidermal growth factor receptor.
Table 3
Concordance between serum HER2 status and HER2 status of CTCs
CTC HER2 negative CTC HER2 positive Total
Serum HER2 positive 3 5 8
Serum HER2 negative 10 3 13
Total 13 8 21a
aConcordance is 71%. CTC, circulating tumor cell; HER, human epidermal growth factor receptor.Available online http://breast-cancer-research.com/content/9/5/R74
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Discussion
Development of metastatic disease is a highly selective proc-
ess. Only a small portion of tumor cells of the primary tumor
have the ability to initiate metastatic growth at a different organ
site. Additional genetic changes accompany tumor progres-
sion and may occur before the recurrence is detected. There-
fore, the phenotype of metastatic disease may be quite
different from that of the primary tumor. Thus, it is important to
establish the HER2 status of the recurrent tumor. However,
biopsies from the metastatic site for re-evaluation of pheno-
type are not routinely obtained. Moreover, the phenotype may
vary between different sites of metastatic disease. For these
reasons, noninvasive re-evaluation of phenotype by CTCs or
shed soluble proteins are attractive alternatives and might
reflect the 'phenotype of the total tumor load' more accurately.
In addition, both serum HER2 and CTC testing has the addi-
tional potential of monitoring the effect of therapy.
Assessment of HER2 status using these methods is also
important for patients with recurrent breast cancer who have
unknown HER2 status. As explained above, there is a signifi-
cant group of newly diagnosed patients with metastatic dis-
ease whose HER2 status is unknown because of lack of
archival primary tumor tissue.
Therefore, in this prospective study the HER2 status was reas-
sessed at the time of identification of metastatic disease by
evaluating serum HER2 in 77 metastatic breast cancer
patients with initially HER2 negative or unknown HER2 status.
Blood samples in 67 patients could be analyzed for HER2-
positive CTCs. In 10 cases biopsies could be obtained from
the metastatic site for HER2 re-evaluation. To our knowledge,
this is the first study that compares reassessment of HER2
status using such different approaches.
Reassessment of HER2 status by HER2 shed antigen
The extracellular domain of the HER2 receptor is shed by pro-
teolysis and can be detected in the serum of breast cancer
patients. The most commonly used cut-off level is 15 ng/ml for
the US Food and Drug Administration approved ELISA. Nor-
mal control individuals are serum HER2 negative based on this
cut-off [20]. At the time of first diagnosis of metastatic disease,
approximately 20% to 50% of patients have positive serum
HER2 status [24,25]. Serum HER2 levels are correlated with
HER2 tissue expression, suggesting that the frequency of
HER2-positive metastases is higher than expected based on
the reported frequency of HER2 positivity in primary tumors
ranging from 15% to 30% [16,23].
Positive serum HER2 status at the time of metastatic disease
has been linked to poor prognosis [26-28]. Moreover, several
studies have indicated that positive serum HER2 status is pre-
dictive of therapy response to Herceptin [29-31]. Moreover,
changes in serum HER2 levels correlate with clinical response
to HER2-targeted therapy, as demonstrated by a recent
pooled analysis of seven trials of first-line trastuzumab therapy
[32]. Increasing levels indicate disease progression, whereas
decreasing levels are associated with a therapeutic response
or stable disease [32,33]. Currently, the serum HER2 test only
has Food and Drug Administration approval for monitoring
changes in serum HER2 levels in patients with metastatic
breast cancer.
In our study, serum HER2 was determined in order to re-eval-
uate HER2 status in 77 metastatic breast cancer patients with
HER2-negative (n = 53), HER2-positive (n = 5), and unknown
HER2 status (n = 19) of the primary tumor. Of these patients,
21% were serum HER2 positive at the time of metastatic dis-
ease. Slightly higher positivity rates in initially HER2-negative
Table 4
HER2 status by serum, CTC, and tissue
Patient ID Serum HER2 HER2 CTC HER2 tissue
#25 Negative ND Negative
#93 Negative ND Negative
#94 Negative ND Negative
#21 Negative ND Negative
#92 Negative ND Negative
#29 Negative ND Negative
#30 Negative ND Negative
#91 Positive Positive Negative
#12 Negative Negative Positive
#17 Positive Positive Positive
CTC, circulating tumor cell; HER, human epidermal growth factor receptor; ND, not detected.Breast Cancer Research    Vol 9 No 5    Fehm et al.
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breast cancer patients at the time of metastatic disease were
observed by Anderson and coworkers (34%) [34] and Fehm
and colleagues (34%) [35] using the serum test. Currently,
such patients are not considered eligible for HER2-targeted
therapy, but based on recent studies it is high likely that such
individuals would respond to Herceptin [29].
The clinical significance of HER2 positive circulating 
tumor cells
Tumors, including metastatic lesions, shed large numbers of
tumor cells into the blood circulation [36], and the presence of
CTCs is of biologic relevance in the metastatic setting. Based
on the hypothesis that the phenotype of CTCs may reflect the
phenotype of metastatic disease, characterization of CTCs
may be useful for reassessment of HER2 status and additional
therapeutic markers [20]. However, this option is limited to
those patients with detectable CTCs. Reported positivity rates
for CTCs in metastatic breast cancer patients range from 20%
to 60% [37,38].
In our prospective study, in which 67 patients could be
included, 21 patients had detectable CTCs (31%). HER2 was
over-expressed in eight of these 21 patients (38%). Meng and
coworkers [20] reassessed the HER2 status in 31 metastatic
patients with CTCs. Nine out of 24 patients with initially HER2-
negative tumors had HER2-positive cells; this rate (38%) is
lower than our observed positivity rate. Four of these nine
patients were treated with a Herceptin-containing chemother-
apy regimen. Two of these patients exhibited partial or com-
plete remission [20].
Hayes and colleagues [39] evaluated the number of HER2-
positive CTCs during the course of treatment by flow cytome-
try in 19 metastatic breast cancer patients. During disease
progression, the HER2 status of CTCs changed from negative
to positive in all cases (n = 3). In contrast, patients responding
to trastuzumab treatment lost their HER2-positive cell fraction.
Meng and coworkers [40] analyzed the urokinase-type plas-
minogen activator receptor and HER2 gene status in individual
breast cancer cells from metastatic breast cancer patients.
Five out of 52 formerly HER2-negative cases acquired HER2
positivity. Interestingly, in two initially HER2-positive patients
with disease progression, CTCs were negative for HER2 after
treatment with trastuzumab.
The major caveat of all of these observational studies, includ-
ing the present study, is the low number of patients included.
Therefore, large clinical trials must be initiated to evaluate fur-
ther whether acquisition of HER2-positive CTCs are predictive
of clinical response to HER2-targeted therapy in a subgroup
of patients with metastatic breast cancer.
Correlation between serum HER2 and HER2-positive 
circulating tumor cells
Elevated serum HER2 levels are associated with HER2 over-
expression and amplification in breast cancer tissue. Never-
theless, discordant results between serum and tissue can be
obtained in a small subset of patients. Differences in serum
HER2 concentrations for a given level of tissue HER2 expres-
sion may be caused by different levels of activators that are
involved in HER2 cleavage, such as metalloproteinase [41].
Molina and colleagues [42] demonstrated that cleavage of the
extracellular domain leads to increased phosphorylation of the
intracellular tyrosine kinase, resulting in an increased receptor
activation. However, both serum HER2 and HER2 over-
expression are predictive of response to Herceptin therapy.
The optimal method for predicting response to therapy is yet
to be determined. In the present study we compared the
HER2 status of CTCs and shed HER2. A similar rate of non-
concordance was reported in studies comparing serum and
tissue HER2 levels in primary breast cancer [34,35]. These
results support the hypothesis that HER2 shedding may
reflect activity of the HER2 shedding machinery and therefore
is not necessarily entirely associated with HER2 amplication
and/or over-expression in tissue or CTCs. In a small subgroup
of patients included in the present study, metastatic tissue
could be tested for HER2 over-expression. In eight patients,
serum HER2 and tissue-based HER2 analysis were negative.
Two out of 10 (20%) patients had HER2-positive metastases.
Only one of the two patients was HER2 positive by serum
analysis and cell-based assay. However, relatively little atten-
tion has been paid to the observed heterogeneity of HER2 sta-
tus within individual tumors, which may contribute to
discordancy among different methods of measurement of
HER2 status as well as to their correlation with conventional
pathologic analysis.
Conclusion
Our study indicates that in patients with initially negative or
unknown HER2 status, elevated serum HER2 levels and/or
HER2-positive CTCs can be detected at the time of identifica-
tion of metastatic disease. However, nonconcordant results
were obtained in 28% of patients using serum and CTCs for
HER2 reassessment. Similar nonconcordance for HER2 lev-
els occurs in primary breast carcinomas but may not occur
with HER2 status of CTCs Therefore, we hypothesize that dif-
ferent mechanisms may account for shedding HER2 as
opposed to its expression. Correlations between clinical
responses to HER2-targeted therapy and findings with each
method should be further studied to help determine when
such treatment should be given.
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